The Oncology Institute, Inc.
TOI
$3.76
$0.092.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 119.80M | 104.41M | 100.27M | 99.90M | 98.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 119.80M | 104.41M | 100.27M | 99.90M | 98.58M |
| Cost of Revenue | 102.30M | 87.16M | 85.63M | 85.54M | 85.55M |
| Gross Profit | 17.50M | 17.25M | 14.64M | 14.37M | 13.03M |
| SG&A Expenses | 26.91M | 25.38M | 24.86M | 26.65M | 27.87M |
| Depreciation & Amortization | 1.81M | 1.78M | 1.71M | 1.57M | 1.52M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 131.01M | 114.32M | 112.20M | 113.75M | 114.94M |
| Operating Income | -11.21M | -9.91M | -11.93M | -13.85M | -16.36M |
| Income Before Tax | -17.14M | -19.59M | -13.18M | -16.11M | -15.48M |
| Income Tax Expenses | -131.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.01M | -19.59M | -13.18M | -16.11M | -15.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.01M | -19.59M | -13.18M | -16.11M | -15.48M |
| EBIT | -11.21M | -9.91M | -11.93M | -13.85M | -16.36M |
| EBITDA | -9.41M | -8.13M | -10.22M | -12.28M | -14.85M |
| EPS Basic | -0.15 | -0.21 | -0.14 | -0.18 | -0.17 |
| Normalized Basic EPS | -0.11 | -0.13 | -0.11 | -0.13 | -0.13 |
| EPS Diluted | -0.15 | -0.21 | -0.15 | -0.18 | -0.17 |
| Normalized Diluted EPS | -0.11 | -0.13 | -0.11 | -0.13 | -0.13 |
| Average Basic Shares Outstanding | 93.20M | 77.10M | 75.66M | 75.52M | 74.75M |
| Average Diluted Shares Outstanding | 93.20M | 77.10M | 75.66M | 75.52M | 74.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |